Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TARS vs CVM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CVM Captures Overall Composite Edge (56.6 HOLD vs 39.5 SELL), While TARS Leads 3–2 on Growth & Valuation Pillars

CVM Overall Winner 6-Pillar Tally: TARS 3 – 2 CVM (1 Tie) Matrix Metrics: TARS 4 – 6 CVM

As of Nov 16, 2026, Cel-Sci Corporation (CVM) captures the overall head-to-head institutional edge over Tarsus Pharmaceuticals, Inc. (TARS) on higher Unified Composite conviction (56.6/100 HOLD vs. 39.5/100 SELL) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while TARS wins 3–2 across the 6-pillar growth and valuation breakdown. TARS trades at $77.83 (63.7x Forward P/E, -9.6% operating margin) versus CVM at $1.59 (23.0x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: CVM earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. TARS 39.5/100 SELL) and 0.65β · 120% Vol risk profile, whereas TARS leads top-line expansion (+63.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: TARS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 62.1); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TARS vs CVM
TARS NASDAQ
Tarsus Pharmaceuticals, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$77.83
-3.06% 1D
Market Cap $3.8B
TTM Revenue $682M
Forward P/E 63.7x
Beta / 30D Vol 0.53β · 45% Vol
Unified Composite Score
39.5 / 100 SELL
Tech 15.0 Fund 44.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 62
RSI-14: 62.1 · SMA20: $72.63 · SMA50: $74.61
CVM NYSE American Head-to-Head Winner
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.65β · 120% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.1 · SMA20: $1.46 · SMA50: $1.66

6-Pillar Scorecard Institutional Category Breakdown (TARS 3 – 2 CVM)

Columns: Metric · TARS · CVM
1. Valuation Multiples CVM
Forward P/E 63.7x 23.0x
Trailing P/E 63.7x 23.0x
PEG Ratio N/M 1.12x
EV / Revenue 5.5x N/M
2. Growth & Scale TARS
Revenue Growth (YoY) +63.9% -62.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $682M $28,558
Market Cap $3.8B $20.9M
3. Profitability & Quality CVM
Gross Margin 83.8% N/A
Operating Margin -9.6% 0.0%
Net Profit Margin -102.9% 0.0%
Return on Equity (ROE) -319.8% -252.5%
4. Balance Sheet & Cash Flow TARS
Cash Generation (TTM) -$4.8M -$17M
Cash Flow Margin -0.7% N/A
Net Cash / Leverage $64M Net Cash $6.6M Net Debt (1.24x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TARS
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 67.5% (4th %ile) N/A (N/A)
Put/Call OI Skew 0.64x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TARS (4) vs CVM (6)
Institutional Metric TARS CVM Criterion Row Edge
Market Capitalization
Scale
$3.8B $20.9M Larger Scale TARS
Trailing P/E Ratio
Valuation
63.7x 23.0x Lower Multiple CVM
Forward P/E Ratio
Valuation
63.7x 23.0x Lower Multiple CVM
Revenue Growth (YoY)
Growth
+63.9% -62.7% Higher Growth TARS
Operating Margin (TTM)
Profitability
-9.6% 0.0% Higher Margin CVM
Net Profit Margin
Profitability
-102.9% 0.0% Higher Margin CVM
Return on Equity (ROE)
Capital Efficiency
-319.8% -252.5% Higher ROE CVM
52-Week Range Position
Momentum
64% ($54–$92) 10% ($1–$8) Stronger Trend TARS
Beta / 30D Volatility
Risk Regime
0.53β · 45% Vol 0.65β · 120% Vol Lower Realized Risk TARS
Unified Institutional Score
Composite Signal
39.5 / 100 (SELL) 56.6 / 100 (HOLD) Higher Composite CVM
Trailing 12M Revenue (USD)
Operating Scale
$682M $28,558 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
83.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.5x EV/Rev 1.12x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$4.8M ($64M Net Cash) -$17M ($6.6M Net Debt (1.24x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TARS +25.5 pp
TARS: +14.33% · CVM: -11.17%
3M Horizon TARS +9.57 pp
TARS: +9.57% · CVM: +0.0%
6M Horizon TARS +31.45 pp
TARS: +23.89% · CVM: -7.56%
1Y Horizon TARS +82.71 pp
TARS: +6.73% · CVM: -75.98%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period TARS Revenue CVM Revenue TARS Op. Margin CVM Op. Margin Margin Leader
FY2012 N/A $0M N/A -6772.3% CVM
FY2013 N/A $0M N/A -12450.1% CVM
FY2014 N/A $0M N/A -9721.4% CVM
FY2021 $60M N/A -21.3% N/A TARS
FY2022 $30M N/A -242.9% N/A TARS
FY2023 $20M N/A -820.5% N/A TARS
FY2024 $180M N/A -65.9% N/A TARS
FY2025 $450M N/A -15.7% N/A TARS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TARS CONSOLIDATION
50d in phase · OBV ACCUMULATION
Current IV 67.5%
IV Percentile 4th %ile
Put/Call OI Skew 0.64x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact TARS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CVM BREAKDOWN
29d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TARS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8B market capitalization and -9.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $20.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TARS vs CVM Key Questions & Quantitative Answers

As of Nov 16, 2026, Cel-Sci Corporation (CVM) captures the overall head-to-head institutional edge over Tarsus Pharmaceuticals, Inc. (TARS) on higher Unified Composite conviction (56.6/100 HOLD vs. 39.5/100 SELL) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while TARS wins 3–2 across the 6-pillar growth and valuation breakdown. TARS trades at $77.83 (63.7x Forward P/E, -9.6% operating margin) versus CVM at $1.59 (23.0x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: CVM earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. TARS 39.5/100 SELL) and 0.65β · 120% Vol risk profile, whereas TARS leads top-line expansion (+63.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: TARS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 62.1); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TARS leads the Growth & Scale pillar: TARS posts +63.9% YoY revenue growth and +0.0% YoY earnings growth on $682M TTM revenue (83.8% gross margin, -9.6% operating margin), compared with CVM at -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2012 to FY2025), TARS cumulative revenue shifted +650.0% while CVM shifted N/A. In operating R&D and SG&A reinvestment, TARS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CVM.

CVM screens cheaper on headline valuation multiples. TARS trades at 63.7x Forward P/E, 63.7x Trailing P/E, N/M PEG, and 5.5x EV/Revenue (-0.7% FCF margin), whereas CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TARS (-319.8% ROE) versus CVM (-252.5% ROE) capital efficiency.

In options market volatility and institutional positioning, TARS carries 67.5% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.64x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.53β · 45% Vol realized risk). By comparison, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.